Free tool
Healthcare stocks
We cover 165 companies in the Healthcare sector. The median market value in the group is $3.69B. Across the group, the median move over the past trading day is +1.25%. 85% of the 159 with a 200-day average trade above it. Price change over the past year runs from −18.2% to +283.3% across the middle 80 percent of the group, with a median of +59.9%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
165 of 2,199 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| PODD | Insulet Corporation | $9.92B | Mid cap | −56.52% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +67.40% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| AVTR | Avantor, Inc. | $9.75B | Mid cap | +9.16% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +85.10% |
| TWST | Twist Bioscience Corporation | $9.50B | Mid cap | +452.83% |
| SYRE | Spyre Therapeutics, Inc. | $9.32B | Mid cap | +547.53% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +100.62% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −10.74% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| IMVT | Immunovant, Inc. | $8.95B | Mid cap | +192.14% |
| HQY | HealthEquity, Inc. | $8.83B | Mid cap | +20.55% |
| BRKR | Bruker Corporation | $8.66B | Mid cap | +64.93% |
| ATR | AptarGroup, Inc. | $8.57B | Mid cap | −2.35% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.48B | Mid cap | +96.32% |
| TXG | 10x Genomics, Inc. | $8.43B | Mid cap | +359.99% |
| ALKS | Alkermes plc | $8.26B | Mid cap | +69.69% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +14.26% |
| HIMS | Hims & Hers Health, Inc. | $7.41B | Mid cap | −26.15% |
| CAI | Caris Life Sciences, Inc. | $7.38B | Mid cap | −27.21% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +63.19% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +19.61% |
| SRRK | Scholar Rock Holding Corporation | $7.09B | Mid cap | +74.77% |
| PACS | PACS Group, Inc. | $7.00B | Mid cap | +272.69% |
| CGON | CG Oncology, Inc. | $7.00B | Mid cap | +210.58% |
| ORKA | Oruka Therapeutics, Inc. | $6.74B | Mid cap | +601.72% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +79.61% |
| BLTE | Belite Bio, Inc | $6.51B | Mid cap | +154.13% |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +212.13% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +168.53% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +138.24% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.24B | Mid cap | +93.10% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.17B | Mid cap | +142.74% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.72% |
| ERAS | Erasca, Inc. | $6.16B | Mid cap | +1016.98% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.13B | Mid cap | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +378.90% |
| STVN | Stevanato Group S.p.A. | $6.08B | Mid cap | +3.23% |
| TVTX | Travere Therapeutics, Inc. | $6.06B | Mid cap | +288.91% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +10.45% |
| DFTX | Definium Therapeutics, Inc. | $6.02B | Mid cap | +354.92% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +36.58% |
| TFX | Teleflex Incorporated | $5.94B | Mid cap | +10.85% |
| CRSP | CRISPR Therapeutics AG | $5.89B | Mid cap | +12.51% |
| XENE | Xenon Pharmaceuticals Inc. | $5.85B | Mid cap | +58.42% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.62B | Mid cap | +77.42% |
| MMED | MiniMed Group, Inc. | $5.60B | Mid cap | +2.33% |
| SHC | Sotera Health Company | $5.57B | Mid cap | +19.04% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | +3.32% |
| GRFS | Grifols, S.A. | $5.44B | Mid cap | −17.62% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.23B | Mid cap | +20.73% |
| HAE | Haemonetics Corporation | $4.93B | Mid cap | +96.13% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +102.62% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +209.16% |
| BLLN | BillionToOne, Inc. | $4.72B | Mid cap | −8.14% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +127.83% |
| WAY | Waystar Holding Corp. | $4.64B | Mid cap | −32.56% |
| ICUI | ICU Medical, Inc. | $4.56B | Mid cap | +44.85% |
| DOCS | Doximity, Inc. | $4.51B | Mid cap | −62.74% |
| RLAY | Relay Therapeutics, Inc. | $4.51B | Mid cap | +486.04% |
| ELVN | Enliven Therapeutics, Inc. | $4.48B | Mid cap | +205.89% |
| CELC | Celcuity Inc. | $4.44B | Mid cap | +87.35% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +49.74% |
| NVST | Envista Holdings Corporation | $4.39B | Mid cap | +30.07% |
| LIVN | LivaNova PLC | $4.37B | Mid cap | +40.92% |
| HTFL | Heartflow, Inc. | $4.34B | Mid cap | +67.19% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.26% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.24B | Mid cap | +49.81% |
| ADPT | Adaptive Biotechnologies Corporation | $4.19B | Mid cap | +107.18% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| LEGN | Legend Biotech Corporation | $4.14B | Mid cap | −38.44% |
| TNGX | Tango Therapeutics, Inc. | $4.13B | Mid cap | +264.73% |
| MANE | Veradermics, Incorporated | $4.11B | Mid cap | +171.13% |
| IDYA | IDEAYA Biosciences, Inc. | $4.10B | Mid cap | +71.91% |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −25.71% |
| ABCL | AbCellera Biologics Inc. | $4.05B | Mid cap | +195.51% |
| RCUS | Arcus Biosciences, Inc. | $4.02B | Mid cap | +211.03% |
| VKTX | Viking Therapeutics, Inc. | $3.99B | Mid cap | +32.19% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +60.12% |
| TLX | Telix Pharmaceuticals Limited | $3.96B | Mid cap | −4.26% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.82B | Mid cap | +233.60% |
| GRAL | GRAIL, Inc. | $3.69B | Mid cap | +150.69% |
| OGN | Organon & Co. | $3.61B | Mid cap | +52.78% |
| GPCR | Structure Therapeutics Inc. | $3.56B | Mid cap | +168.82% |
| QURE | uniQure N.V. | $3.54B | Mid cap | +228.30% |
| OPCH | Option Care Health, Inc. | $3.54B | Mid cap | −15.75% |
| VCYT | Veracyte, Inc. Common Stock | $3.54B | Mid cap | +49.04% |
| NHC | National HealthCare Corporation | $3.52B | Mid cap | +103.48% |
| PLSE | Pulse Biosciences, Inc. | $3.50B | Mid cap | +197.94% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +196.22% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.33B | Mid cap | +275.00% |
| MBX | MBX Biosciences, Inc. | $3.30B | Mid cap | +394.02% |
| NAMS | NewAmsterdam Pharma Company N.V. | $3.27B | Mid cap | +10.69% |
| WRBY | Warby Parker Inc. | $3.24B | Mid cap | −0.61% |
| CLDX | Celldex Therapeutics, Inc. | $3.24B | Mid cap | +87.96% |
| TMDX | TransMedics Group, Inc. | $3.23B | Mid cap | −18.59% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +88.75% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.20B | Mid cap | +26.21% |
| IRON | Disc Medicine, Inc. | $3.16B | Mid cap | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +58.44% |
| ALMS | Alumis Inc. | $2.98B | Mid cap | +388.98% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +82.91% |
| ZLAB | Zai Lab Limited | $2.94B | Mid cap | −23.10% |
| BKD | Brookdale Senior Living Inc. | $2.91B | Mid cap | +59.90% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.89B | Mid cap | +637.70% |
| ALHC | Alignment Healthcare, Inc. | $2.82B | Mid cap | −12.77% |
| ACHC | Acadia Healthcare Company, Inc. | $2.78B | Mid cap | +34.73% |
| RGC | Regencell Bioscience Holdings Limited | $2.74B | Mid cap | −54.89% |
| VRDN | Viridian Therapeutics, Inc. | $2.74B | Mid cap | +30.21% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +56.96% |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | Mid cap | +178.70% |
| PRVA | Privia Health Group, Inc. | $2.71B | Mid cap | −0.93% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +237.59% |
| CDNA | CareDx, Inc. | $2.63B | Mid cap | +298.43% |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.62B | Mid cap | +2.09% |
| PHVS | Pharvaris N.V. | $2.62B | Mid cap | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −9.60% |
| WGS | GeneDx Holdings Corp. | $2.61B | Mid cap | −28.28% |
| PGEN | Precigen, Inc. | $2.60B | Mid cap | +82.91% |
| TRVI | Trevi Therapeutics, Inc. | $2.56B | Mid cap | +146.57% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +65.32% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +107.86% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +17.16% |
| BHC | Bausch Health Companies Inc. | $2.50B | Mid cap | −7.81% |
| NUVB | Nuvation Bio Inc. | $2.49B | Mid cap | +146.53% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +316.68% |
| ATRC | AtriCure, Inc. | $2.48B | Mid cap | +28.65% |
| PBH | Prestige Consumer Healthcare Inc. | $2.46B | Mid cap | −21.64% |
| RAPP | Rapport Therapeutics, Inc. | $2.46B | Mid cap | +249.76% |
| BFLY | Butterfly Network, Inc. | $2.41B | Mid cap | +483.23% |
| OCUL | Ocular Therapeutix, Inc. | $2.39B | Mid cap | −8.34% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +42.20% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +37.69% |
| MLYS | Mineralys Therapeutics, Inc. | $2.32B | Mid cap | +78.70% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.32B | Mid cap | +46.03% |
| ALMR | Alamar Biosciences, Inc. | $2.29B | Mid cap | +50.09% |
| GENB | Generate Biomedicines, Inc. | $2.27B | Mid cap | +61.11% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.27B | Mid cap | +4.09% |
| URGN | UroGen Pharma Ltd. | $2.27B | Mid cap | +150.59% |
| ADUS | Addus HomeCare Corporation | $2.26B | Mid cap | +3.81% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +9.42% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.23B | Mid cap | +38.03% |
| VCEL | Vericel Corporation | $2.21B | Mid cap | +20.76% |
| ZBIO | Zenas BioPharma, Inc. | $2.20B | Mid cap | +103.93% |
| CLOV | Clover Health Investments, Corp. | $2.19B | Mid cap | +56.14% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +58.21% |
| XRAY | DENTSPLY SIRONA Inc. | $2.19B | Mid cap | −21.70% |
| NEO | NeoGenomics, Inc. | $2.19B | Mid cap | +160.31% |
| XNCR | Xencor, Inc. Common Stock | $2.18B | Mid cap | +265.79% |
| BHVN | Biohaven Ltd. | $2.17B | Mid cap | −3.75% |
| STOK | Stoke Therapeutics, Inc. | $2.16B | Mid cap | +77.32% |
| ESTA | Establishment Labs Holdings Inc. | $2.15B | Mid cap | +77.45% |
| KLRA | Kailera Therapeutics, Inc. | $2.14B | Mid cap | −31.73% |
| ADMA | ADMA Biologics, Inc. | $2.14B | Mid cap | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $2.14B | Mid cap | +195.71% |
| HCM | HUTCHMED (China) Limited | $2.13B | Mid cap | −23.04% |
| NBTX | Nanobiotix S.A. | $2.11B | Mid cap | +321.42% |
| PIII | P3 Health Partners Inc. | $2.06B | Mid cap | +35.72% |
| CMPS | COMPASS Pathways plc | $2.06B | Mid cap | +224.89% |
| NVCR | NovoCure Limited | $2.05B | Mid cap | +50.60% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +26.87% |
| TSHA | Taysha Gene Therapies, Inc. | $2.02B | Mid cap | +112.33% |
| PRGO | Perrigo Company plc | $2.01B | Mid cap | −36.97% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.